CJC-1295 vs Sermorelin: Which Is Better?

Both CJC-1295 and Sermorelin are GHRH analogues — they work by mimicking the body's own growth hormone releasing hormone signal. But they differ meaningfully in potency, half-life, clinical history, and legal availability. This comparison covers what each compound does, where each excels, and the key factor most guides don't adequately address: the significant difference in regulatory status.

Aspect	Sermorelin	CJC-1295
Type	Natural GHRH fragment (aa 1–29)	Modified GHRH fragment — stabilised with tetrasubstituted amino acids
Half-life	~10–20 minutes	No DAC: ~30 min \| With DAC: ~8 days
Potency vs natural GHRH	Equivalent to endogenous GHRH (natural)	2–10x more potent per mcg (modifications protect from enzymatic degradation)
Clinical history	FDA-approved for paediatric GH deficiency; prescribed off-label by anti-ageing practitioners	Research-only; no FDA approval; not available from licensed pharmacies
Prescription availability	Yes — available via compounding pharmacies (though subject to FDA actions)	No — research compound only
Typical dose	0.2–0.3 mg (200–300 mcg) per injection	No DAC: 100–200 mcg \| With DAC: 1–2 mg/week
Injection frequency	Once daily (before bed preferred)	No DAC: 2–3x daily \| With DAC: 1–2x weekly
GH pulsatility	Preserves natural pulsatile release — very physiological	No DAC: preserves pulsatility \| With DAC: may blunt pulsatility
IGF-1 impact	Moderate — less potent per dose than CJC-1295	Stronger IGF-1 elevation reported in studies
Side effect profile	Generally well tolerated; occasional injection site reactions, flushing, nausea	Similar profile; With DAC associated with more water retention

Where Sermorelin Wins

Clinical safety record — it has been prescribed by physicians for decades. Its safety profile in humans is better documented than CJC-1295.

Regulatory availability — prescriptions are possible via anti-ageing and hormone medicine practitioners. This means quality-controlled pharmaceutical-grade access, not just research peptides.

Natural mechanism — it replicates the body's own GHRH signal most closely, preserving physiological pulsatility without modification concerns.

Less controversy — Sermorelin sits in a more legally comfortable position than research-only peptides like CJC-1295.

Where CJC-1295 Wins

Higher potency per mcg — structural modifications make it more resistant to enzymatic degradation, producing a larger GH signal per dose in comparative studies.

Longer half-life (No DAC) — 30 minutes vs Sermorelin's 10–20 minutes means more time for the pituitary to respond per injection.

With DAC convenience — the week-long half-life variant allows once-weekly dosing that sermorelin simply cannot match.

Better stacking data with Ipamorelin — the CJC-1295 + Ipamorelin combination is the most studied and discussed GH secretagogue stack in the research community.

The Regulatory Reality

Sermorelin is available via prescription from licensed physicians who specialize in hormone medicine. CJC-1295 is not — it exists only as a research compound. This distinction matters if you're evaluating risk and quality control: pharmaceutical-grade sermorelin from a compounding pharmacy has different quality assurances than research-grade CJC-1295.

However, FDA actions from 2023–2024 have complicated compounding pharmacy access for peptides including sermorelin, and the landscape is evolving. The practical availability of each compound has shifted and varies by jurisdiction.

CJC-1295 — Research Grade

Available from Base Peptides with certificate of analysis.

View at Base Peptides

Research use only. CJC-1295 is not FDA-approved for human therapeutic use. Sermorelin is available by prescription in some jurisdictions. This article is for educational purposes only.

GH Peptides Guides

→ CJC-1295 + Ipamorelin Dosage Protocol → Ipamorelin vs CJC-1295 Comparison → Best Time to Take CJC-1295 → Ipamorelin Side Effects → Can You Take CJC-1295 Alone?→ How GH Peptides Work → GHRH vs GHRP Peptides